Heat Biologics, Inc. (NASDAQ:HTBX)

Heat Biologics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of various cellular therapeutic vaccines for a range of cancers and infectious diseases. The Company’s products under development include HS-110 for the treatment of non-small cell lung cancer, HS-410 for the bladder cancer treatment, HS-310 to treat ovarian cancer and HS-510 for treating triple negative breast cancer. Heat Biologics, Inc. is based in Chapel Hill, North Carolina.

Heat Biologics, Inc. (NASDAQ:HTBX)’s Financial Overview

Heat Biologics, Inc. (NASDAQ:HTBX) declined -3.69% yesterday to close its trading session at $2.87. The company has 1 year Price Target of $4.88. Heat Biologics, Inc. has 52-Week high of $4.71 and 52-Week Low of $0.4. The stock touched its 52-Week High on Jan 6, 2016 and 52-Week Low on May 13, 2016. The stock traded with the volume of 4.29 Million shares yesterday. The firm shows the market capitalization of $68.51 Million.

Heat Biologics, Inc. (NASDAQ:HTBX) reported its last quarterly earnings on Sep 16 where the firm reported its Actual EPS of $-0.08/share against the analyst consensus estimate of $-0.15/share. The difference between the actual and expected EPS is $0.07 a share with a surprise factor of 46.7%.

The firm is trading with SMA20 of 74.42 Percent, SMA50 of 98.34 Percent and SMA200 of 173.65 percent. Heat Biologics, Inc. has P/S value of 342.53 while its P/B value stands at 7.97. Similarly, the company has Return on Assets of -140.5 percent, Return on Equity of -316 percent and Return on Investment of 0 Percent. The company shows Gross Margin and Operating Margin of 0 percent and 0 percent respectively.

Many brokerage firms are involved in issuing their ratings on Heat Biologics, Inc. (NASDAQ:HTBX). On 20-Jun-16 ROTH Capital Initiated Heat Biologics, Inc. Stock  to Buy. Another firm also rated the stock on 8-Jan-16 where Noble Financial Initiated the stock to Buy.

The Stock currently has Analyst’ mean Recommendation of 2 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 2 analysts offering 12-month price forecasts for Heat Biologics Inc have a median target of 4.88, with a high estimate of 7.00 and a low estimate of 2.75. The median estimate represents a +69.86% increase from the last price of 2.87.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Host Hotels & Resorts, Inc. (NYSE:HST)

Host Hotels & Resorts, Inc. is a lodging real estate company that currently owns or holds controlling interests in upper upscale and luxury hotel properties primarily operated under premium brands. Host Hotels & Resorts will be the premier lodging real estate company. Creating value through aggressive asset management and disciplined capital allocation to generate superior performance would maximize shareholders’ returns through a combination of dividends, growth in funds from operations and increasing asset value.

Host Hotels & Resorts, Inc. (NYSE:HST)’s Financial Outlook

The 17 analysts offering 12-month price forecasts for Host Hotels & Resorts Inc have a median target of 16.00, with a high estimate of 18.00 and a low estimate of 14.00. The median estimate represents a -10.31% decrease from the last price of 17.84.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, Host Hotels & Resorts, Inc. has a Consensus Recommendation of 2.81. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock gained 3.12% and closed its last trading session at $17.84. The company has the market capitalization of $13.2 Billion. The stock has 52-week high of $18.56 and 52-Week low of $12.17. The firm touched its 52-Week high on Aug 23, 2016 and 52-Week low on Jan 20, 2016. The company has volume of 26.02 Million shares. The company has a total of 739.86 Million shares outstanding.

Host Hotels & Resorts, Inc. (NYSE:HST) in the last quarter reported its actual EPS of $0.37/share where the analyst estimated EPS was $0.36/share. The difference between the actual and Estimated EPS is $0.01. This shows a surprise factor of 2.8 percent.

The company has YTD performance of 20.89 percent. Beta for Host Hotels & Resorts, Inc. stands at 1.32 while its ATR (average true range) is 0.45. The company has Weekly Volatility of 2.58%% and Monthly Volatility of 2.97%%.

Host Hotels & Resorts, Inc. has distance from 20-day Simple Moving Average (SMA20) of 9.07%, Distance from 50-Day Simple Moving Average of 12.44 percent and Distance from 200-Day Simple Moving Average of 11.62%.

The Company currently has ROA (Return on Assets) of 6.9 percent, Return on Equity (ROE) of 11.3 Percent and Return on Investment (ROI) of 5.9% with Gross margin of 0 percent and Operating & Profit margin of 12.5% and 14.7% respectively.